GEN Roundup: No Detail Is Too Small in Bioprocess Scaleup
A Change in Scale Can Change Everything
Amid Election Clamor, Research Issues Surface
Sounds of Science Podcast
Molecular Dx Has Your (Copy) Number
CNV Detection and Analysis Tools Are Being Used To Fill Genetic Diagnostic Gaps
10 Takeover Targets of 2016
Which Biopharmas Do Wall Street Watchers View As Top Buyout Candidates?
Status of Cancer Clinical Trials
The Institute of Medicine of the National Academies reports that the state of cancer clinical trials in the U.S. has reached crisis mode. The study cites a number of factors responsible for this situation, such as too much bureaucracy, wasted funds, and lack of patient enrollment. Do you think that the Institute’s proposed goals of (1) improving the speed and efficiency of the design, launch, and conduct of clinical trials, (2) making optimal use of scientific innovations, (3) achieving better selection, prioritization, support, and completion of clinical trials, and (4) fostering expanded participation of both patients and physicians will effectively address the crisis in cancer clinical trials?